09:27 AM EDT, 05/14/2025 (MT Newswires) -- Tempus AI ( TEM ) said Wednesday it has entered a strategic collaboration with Boehringer Ingelheim to advance the latter's cancer pipeline.

Financial terms weren't disclosed.

Under the new, multi-year partnership, Boehringer will have access to Tempus' de-identified database which has molecular, clinical, and imaging data, and its analytical platform, Lens, Tempus added.

The parties intend to identify data derived from patient groups for biomarker development and patient stratification, and develop drug combination hypotheses, the company said.

Tempus' stock was up nearly 3% in recent Wednesday premarket activity.